CLRB logo

CLRB Cellectar Biosciences, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.89
-0.04 (-3.81%)

Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstr…

Market Cap: $8.89Mwww.cellectar.com

Price

No data yet.

Social Signal Score

36
5d
—
30d
23
3 mentions
—
60d
42
5 mentions
—
90d
42
5 mentions
—
news: 5

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 1Sell 0Strong Sell 0
Avg price target$11+1142.7%
Low $11Median $11High $11
Current Consensus

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-9.27
$-10.35–$-8.19
2 analysts
FY2026
$-2.25
$-2.32–$-2.17
3 analysts
FY2027
$-2.03
$-2.35–$-1.52
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
James V. Caruso
Sector
Healthcare
Industry
Biotechnology
Employees
11
Beta
0.58
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-14.99
www.cellectar.com